Sandra Springer, MD

• Alexei Zelenev
• Frederick Altice
• Gerald Friedland
• Jaimie Meyer
• Jeffrey Wickersham
• Kaveh Khoshnood
• Marwan Mikheal Azar
• Maxim Polonsky
• Robert Bruce
• Russell Barbour
• Tami Sullivan

Acquired Immunodeficiency Syndrome; Alcoholism; Buprenorphine; HIV; Naloxone; Naltrexone; Opioid-Related Disorders; Prisoners; Risk-Taking; Substance-Related Disorders

Behavioral Health; HIV/AIDS; Substance Use, Addiction

• Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy.Springer SA, Chen S, Altice F. Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Care 2009, 21:976-83.
• A pilot survey of attitudes and knowledge about opioid substitution therapy for HIV-infected prisoners.Springer SA, Bruce RD. A pilot survey of attitudes and knowledge about opioid substitution therapy for HIV-infected prisoners. Journal Of Opioid Management 2008, 4:81-6.
• Antiretroviral treatment regimen outcomes among HIV-infected prisoners.Springer SA, Friedland GH, Doros G, Pesanti E, Altice FL. Antiretroviral treatment regimen outcomes among HIV-infected prisoners. HIV Clinical Trials 2007, 8:205-12.
• Managing HIV/AIDS in correctional settings.Springer SA, Altice FL. Managing HIV/AIDS in correctional settings. Current HIV/AIDS Reports 2005, 2:165-70.
• Correlates of HIV infection among incarcerated women: implications for improving detection of HIV infection.Altice FL, Marinovich A, Khoshnood K, Blankenship KM, Springer SA, Selwyn PA. Correlates of HIV infection among incarcerated women: implications for improving detection of HIV infection. Journal Of Urban Health : Bulletin Of The New York Academy Of Medicine 2005, 82:312-26.
• Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community.Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clinical Infectious Diseases : An Official Publication Of The Infectious Diseases Society Of America 2004, 38:1754-60.
• Partner violence and health among HIV-infected jail detainees.Meyer JP, Wickersham JA, Fu JJ, Brown SE, Sullivan TP, Springer SA, Altice FL. Partner violence and health among HIV-infected jail detainees. International Journal Of Prisoner Health 2013, 9:124-41.
• Contribution of substance use disorders on HIV treatment outcomes and antiretroviral medication adherence among HIV-infected persons entering jail.Chitsaz E, Meyer JP, Krishnan A, Springer SA, Marcus R, Zaller N, Jordan AO, Lincoln T, Flanigan TP, Porterfield J, Altice FL. Contribution of substance use disorders on HIV treatment outcomes and antiretroviral medication adherence among HIV-infected persons entering jail. AIDS And Behavior 2013, 17 Suppl 2:S118-27.
• Post-release substance abuse outcomes among HIV-infected jail detainees: results from a multisite study.Krishnan A, Wickersham JA, Chitsaz E, Springer SA, Jordan AO, Zaller N, Altice FL. Post-release substance abuse outcomes among HIV-infected jail detainees: results from a multisite study. AIDS And Behavior 2013, 17 Suppl 2:S171-80.
• Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community.Springer SA, Altice FL, Herme M, Di Paola A. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community. Contemporary Clinical Trials 2014, 37:209-18.
• An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone.Vagenas P, Di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL, Springer SA. An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone. Journal Of Substance Abuse Treatment 2014, 47:35-40.
• Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate.Meyer JP, Cepeda J, Wu J, Trestman RL, Altice FL, Springer SA. Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate. JAMA Internal Medicine 2014, 174:721-9.
• Validation of a Brief Measure of Opioid Dependence: The Rapid Opioid Dependence Screen (RODS).Wickersham JA, Azar MM, Cannon CM, Altice FL, Springer SA. Validation of a Brief Measure of Opioid Dependence: The Rapid Opioid Dependence Screen (RODS). Journal Of Correctional Health Care : The Official Journal Of The National Commission On Correctional Health Care 2015, 21:12-26.
• The impact of DSM-IV mental disorders on adherence to combination antiretroviral therapy among adult persons living with HIV/AIDS: a systematic review.Springer SA, Dushaj A, Azar MM. The impact of DSM-IV mental disorders on adherence to combination antiretroviral therapy among adult persons living with HIV/AIDS: a systematic review. AIDS And Behavior 2012, 16:2119-43.
• Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners.Springer SA, Qiu J, Saber-Tehrani AS, Altice FL. Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. PloS One 2012, 7:e38335.
• Adherence to HIV treatment and care among previously homeless jail detainees.Chen NE, Meyer JP, Avery AK, Draine J, Flanigan TP, Lincoln T, Spaulding AC, Springer SA, Altice FL. Adherence to HIV treatment and care among previously homeless jail detainees. AIDS And Behavior 2013, 17:2654-66.
• Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community - a potential conduit to improved HIV treatment outcomes.Saber-Tehrani AS, Springer SA, Qiu J, Herme M, Wickersham J, Altice FL. Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community - a potential conduit to improved HIV treatment outcomes. Contemporary Clinical Trials 2012, 33:436-44.
• Public health implications for adequate transitional care for HIV-infected prisoners: five essential components.Springer SA, Spaulding AC, Meyer JP, Altice FL. Public health implications for adequate transitional care for HIV-infected prisoners: five essential components. Clinical Infectious Diseases : An Official Publication Of The Infectious Diseases Society Of America 2011, 53:469-79.
• Drug Treatment as HIV Prevention Among Women and Girls Who Inject Drugs From a Global Perspective: Progress, Gaps, and Future Directions.Springer SA, Larney S, Alam-Mehrjerdi Z, Altice FL, Metzger D, Shoptaw S. Drug Treatment as HIV Prevention Among Women and Girls Who Inject Drugs From a Global Perspective: Progress, Gaps, and Future Directions. Journal Of Acquired Immune Deficiency Syndromes (1999) 2015, 69 Suppl 2:S155-61.
• Commentary on Larney (2010): a call to action-opioid substitution therapy as a conduit to routine care and primary prevention of HIV transmission among opioid-dependent prisoners.Springer SA. Commentary on Larney (2010): a call to action-opioid substitution therapy as a conduit to routine care and primary prevention of HIV transmission among opioid-dependent prisoners. Addiction (Abingdon, England) 2010, 105:224-5.
• Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment.Springer SA, Chen S, Altice FL. Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment. Journal Of Urban Health : Bulletin Of The New York Academy Of Medicine 2010, 87:592-602.
• Correction: The Impact of Implementing a Test, Treat and Retain HIV Prevention Strategy in Atlanta among Black Men Who Have Sex with Men with a History of Incarceration: A Mathematical Model.Lima VD, Graf I, Beckwith CG, Springer S, Altice FL, Coombs D, Kim B, Messina L, Montaner JS, Spaulding A. Correction: The Impact of Implementing a Test, Treat and Retain HIV Prevention Strategy in Atlanta among Black Men Who Have Sex with Men with a History of Incarceration: A Mathematical Model. PloS One 2015, 10:e0128734.
• HIV-infected men who have sex with men, before and after release from jail: the impact of age and race, results from a multi-site study.Vagenas P, Zelenev A, Altice FL, Di Paola A, Jordan AO, Teixeira PA, Frew PM, Spaulding AC, Springer SA. HIV-infected men who have sex with men, before and after release from jail: the impact of age and race, results from a multi-site study. AIDS Care 2016, 28:22-31.
• Improving healthcare for incarcerated women.Springer SA. Improving healthcare for incarcerated women. Journal Of Women's Health (2002) 2010, 19:13-5.
• Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system.Springer SA, Brown SE, Di Paola A. Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system. Drug And Alcohol Dependence 2015, 157:158-65.
• Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine.Makarenko I, Mazhnaya A, Polonsky M, Marcus R, Bojko MJ, Filippovych S, Springer S, Dvoriak S, Altice FL. Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine. Drug And Alcohol Dependence 2016, 165:213-20.
• Co-calibration of two self-reported measures of adherence to antiretroviral therapy.Nance RM, Delaney JA, Golin CE, Wechsberg WM, Cunningham C, Altice F, Christopoulos K, Knight K, Quan V, Gordon MS, Springer S, Young J, Crane PK, Mayer KH, Mugavero MJ, Del Rio C, Kronmal RA, Crane HM. Co-calibration of two self-reported measures of adherence to antiretroviral therapy. AIDS Care 2017, 29:464-468.
• Gender Differences in HIV Risk Behaviors Among Persons Involved in the U.S. Criminal Justice System and Living with HIV or at Risk for HIV: A "Seek, Test, Treat, and Retain" Harmonization Consortium.Loeliger KB, Biggs ML, Young R, Seal DW, Beckwith CG, Kuo I, Gordon MS, Altice FL, Ouellet LJ, Cunningham WE, Young JD, Springer SA. Gender Differences in HIV Risk Behaviors Among Persons Involved in the U.S. Criminal Justice System and Living with HIV or at Risk for HIV: A "Seek, Test, Treat, and Retain" Harmonization Consortium. AIDS And Behavior 2017, 21:2945-2957.
• Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community.Springer SA, Di Paola A, Azar MM, Barbour R, Krishnan A, Altice FL. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug And Alcohol Dependence 2017, 174:158-170.
• HIV in people reincarcerated in Connecticut prisons and jails: an observational cohort study.Meyer JP, Cepeda J, Springer SA, Wu J, Trestman RL, Altice FL. HIV in people reincarcerated in Connecticut prisons and jails: an observational cohort study. The Lancet. HIV 2014, 1:e77-e84.
• Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community.Di Paola A, Lincoln T, Skiest DJ, Desabrais M, Altice FL, Springer SA. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community. Contemporary Clinical Trials 2014, 39:256-68.
• A comparison of psychiatric diagnoses among HIV-infected prisoners receiving combination antiretroviral therapy and transitioning to the community.Di Paola A, Altice FL, Powell ML, Trestman RL, Springer SA. A comparison of psychiatric diagnoses among HIV-infected prisoners receiving combination antiretroviral therapy and transitioning to the community. Health & Justice 2014, 2.